17β-Estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males

Do Dai-Do, Emma Espinosa, Guizhen Liu, Ton J. Rabelink, Friedgard Julmy, Zhihong Yang, Felix Mahler, Thomas F. Lüscher

Abstract

Objectives: Cardiovascular disease is rare in premenopausal women, but increases after the menopause when hormone replacement therapy reduces coronary events. Vascular smooth muscle cell (SMC) proliferation and migration occur in atherosclerosis, restenosis and venous graft disease. We studied the effects of 17β-estradiol on SMC proliferation and migration. Methods: SMC were cultured from saphenous veins of postmenopausal women and age-matched men. Cell growth was determined by 3H-thymidine incorporation and cell counting. Migration of SMC was assessed in 4-well chambers. SMC were seeded in one corner and PDGF-BB in filter paper glued onto the opposite wall. Results: PDGF-BB (5 ng/ml for 24 h) similarly stimulated 3H-thymidine incorporation in female (511 ± 57%; n = 8) and male (528 ± 62%; n = 12) SMC. This was reduced by 17β-estradiol (10⁻⁸-10⁻⁶ M; female 313 ± 52%; male 337 ± 54%; P < 0.05). PDGF-BB increased the number of SMC (P < 0.0001 at 10 days) obtained from females (153 ± 3%; n = 5) and males (150 ± 4%; n = 5), which was inhibited by 17β-estradiol (10⁻⁶ M; female 134 ± 7%; male 128 ± 5%; P < 0.05). Similar results were obtained with basic fibroblast growth factor. In contrast to 17β estradiol, another steroid (dexamethasone) had no effects on 3H-thymidine incorporation in these cells stimulated with PDGF-BB. PDGF-BB (0.01-1 ng) stimulated SMC migration (P < 0.05) which was inhibited by 17β-estradiol (10⁻¹⁰-10⁻⁶ M; n = 5; P < 0.005). Conclusion: 17β-Estradiol inhibits growth-factor-induced SMC proliferation and migration regardless of gender. These effects of 17β-estradiol may contribute to its cardiovascular protective properties in postmenopausal women during replacement therapy.

Keywords: FGF; Estrogen; PDGF; Human, saphenous vein

1. Introduction

Coronary artery disease is the leading cause of death in industrialized countries. Percutaneous transluminal coronary angioplasty (PTCA) and bypass surgery are well-established methods of treating these patients [1,2]. However, both procedures do not prevent progression of the disease. Furthermore, PTCA is associated with restenosis and bypass surgery with graft disease, particularly venous graft disease [1,2]. Cell proliferation and migration are believed to be critical for accumulation of smooth muscle cells (SMC) in the intima, and this may be important for vascular luminal narrowing [3,4]. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) released from platelets and activated vascular cells are considered to be important in triggering SMC proliferation and migration [3,4].
The incidence of coronary artery disease in premenopausal women is lower than in men and increases after the menopause [5-7]. Estrogen replacement therapy in postmenopausal women markedly reduces cardiovascular events [5,8,9]. Hence, female sex hormones and 17β-estradiol in particular may protect women against vascular disease [5]. However, the cardiovascular protective effects of estrogens remain unclear, although it has been documented that they inhibit vasoconstriction in an endothelium-dependent as well as endothelium-independent manner [10-14]. Furthermore, estrogens favorably change the lipid metabolic profile [5,15]. More recent studies on the rat aorta and human coronary artery circulation demonstrated gender differences in endothelial function modulating vascular tone [16,17]. This study was designed to investigate whether a gender difference concerning the effects of 17β-estradiol on SMC proliferation and migration exists in cells obtained from postmenopausal women and age-matched men.

2. Methods

2.1. Materials

Bovine serum albumin, 17β-estradiol, dexamethasone, monoclonal antibody against α-smooth muscle actin and cytosine-β-D-arabinofuranoside were obtained from Sigma (Buchs, Switzerland), recombinant platelet-derived growth factor-BB, basic fibroblast growth factor, fibronectin, and agarose and all tissue culture materials were obtained from Gibco (Basel, Switzerland). 3H-Methylthymidine was from Amersham (Zürich, Switzerland), trichloroacetic acid from Fluka (Buchs, Switzerland), and blotting paper (GB004) from Schleicher and Schuell (Feldbach, Switzerland).

2.2. Isolation and cultivation of cells

Vascular SMC were isolated from saphenous veins of 8 postmenopausal women without estrogen replacement therapy (mean age 65 years, range 57-72) and 12 age matched men (mean age 62 years, range 55-71; n.s.) undergoing coronary bypass surgery by explant technique as described previously [18]. Vascular SMC were cultured in phenol red-free Dulbecco’s Modified Eagle Medium (DMEM) containing 20% fetal calf serum (FCS) and 2 mM L-glutamine and 10 mM HEPES buffer solution, 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified atmosphere (37°C; 95% air/5% CO₂). In certain experiments, cells were grown in culture medium containing phenol red. Culture medium was replaced every 3 days. Cells were passaged by trypsinization (0.05% trypsin-EDTA). Experiments were performed between passages 3 and 6. SMC were characterized by indirect immunofluorescence staining using specific anti-smooth-muscle α-actin antibodies [18,19].

2.3. Assay of cell mitogenicity

Cells were seeded on 12-well plates (density: 10⁴/ml for 24 h to allow attachment). Culture media were then replaced with phenol-red-free, serum-free DMEM medium containing all ingredients as described above and 0.2% bovine serum albumin (BSA) instead of FCS. Cells in serum-free DMEM medium were incubated with or without 17β-estradiol (10⁻⁸-10⁻⁵ M) for 48 h before stimulation with PDGF-BB (5 ng/ml) or bFGF (5 ng/ml). 3H-Thymidine incorporation was assayed as described previously [18,19]. Incorporated radioactivity was measured with a β-counter (ICN, Intertechnique, France). In parallel experiments, cell number was counted. Quiescent SMC were treated with or without 17β-estradiol (10⁻⁶ M) or vehicle (2-hydroxypropyl-β-cyclodextrin) for 48 h and then stimulated with PDGF-BB (5 ng/ml) every 2 days with or without 17β-estradiol (10⁻⁶ M). Cell number was counted at day 10 (Coulter counter; England).

2.4. Migration of smooth muscle cells

Migration assays were performed in 4-well chambers coated with fibronectin (5 μg/ml). VSMC 3 × 10⁵ in 100 μl DMEM without phenol red supplemented with 20% FCS were seeded in one corner of the chambers and incubated overnight to allow for cell attachment. The cells were then washed 3 times with serum-free medium containing 0.2% BSA and a start line was drawn along the edge of the attached cells. On the opposite side of the chamber, an 8-mm² filter paper preincubated in 0.1% agarose containing PDGF-BB (0.01-1 ng/filter) was glued onto the opposite wall of the chambers by using preheated (50°C) 0.5% agarose. 800 μl serum-free medium supplemented with 50 mM cytosine-β-D-arabinofuranoside were added to each chamber. The cells were incubated for another 48 h and at the end of the migration assay the cells were then washed with PBS, fixed with 4% paraformaldehyde, and stained with hematoxylin. The migration of VSMC was assessed by blinded counting of the number of cells observed across the start line using light microscopy. To investigate possible inhibitory effects of 17β-estradiol on PDGF-BB-induced VSMC migration, the cells were pretreated with 17β-estradiol for 24 h. The migration assays were then performed with PDGF-BB at the optimal stimulatory dose (1 ng/filter).

2.5. Statistical analysis

All experiments were performed in triplicates. Data are presented as percent of control and given as means ± s.e.m. One-way factorial analysis of variance (ANOVA) was used for statistical analysis. n equals number of patients. A two-tailed P-value smaller than 0.05 was considered significant.
3. Results

3.1. Effects of estrogen on cell proliferation

PDGF-BB (0.01 to 10 ng/ml) concentration-dependently stimulated $^3$H-thymidine incorporation which reached a maximum at 5 ng/ml. PDGF-BB (5 ng/ml) increased $^3$H-thymidine incorporation into vascular smooth muscle cells obtained from postmenopausal women (511 ± 57% above control; Fig. 1 left; n = 8; P < 0.0001 versus control) and by 528 ± 62% in cells obtained from age-matched men (Fig. 1 right; n = 12; P < 0.0001 versus control). 17β-Estradiol (10$^{-8}$–10$^{-6}$ M) reduced $^3$H-thymidine incorporation into vascular smooth muscle cells from postmenopausal women to 313 ± 52% (n = 8; P < 0.05 versus PDGF-BB alone) and to a similar degree also in those obtained from men (337 ± 54%; n = 12; P < 0.05 versus PDGF-BB alone). The vehicle, 2-hydroxypropyl-β-cyclodextrin, had no effects on PDGF-BB-stimulated cell proliferation. If vascular smooth muscle cells were cultured in medium containing phenol red, no inhibitory effect of 17β-estradiol on PDGF-BB-induced $^3$H-thymidine incorporation was observed. After 10 days of stimulation with PDGF-BB (5 ng/ml), the number of vascular smooth muscle cells obtained from women (Fig. 2, left; 153 ± 3%, n = 5; P < 0.0001 versus control) as well as from men was increased (Fig. 2, right; 150 ± 4%, n = 5; P < 0.0001 versus control). 17β-Estradiol (10$^{-6}$ M) reduced cell numbers in female cells (134 ± 7%, n = 5; P < 0.05 versus PDGF-BB alone) as well as in male cells (128 ± 5%; n = 5; P < 0.05 versus PDGF-BB alone), while the hormone alone had no effect on cell number (Fig. 2; n.s. versus control).

In contrast to 17β-estradiol, dexamethasone (10$^{-9}$–10$^{-6}$ M), also a steroid, had no effects on $^3$H-thymidine incorporation into cells stimulated with PDGF-BB (5 ng/ml; Fig. 3; n = 15, 8 males and 7 females).

Similar results to those with PDGF were obtained in cells stimulated with bFGF, where 17β-estradiol also inhibited the effects of the growth factor on $^3$H-thymidine incorporation (n = 9, 4 females and 5 males; P < 0.05, Fig. 4 right). Heparin (0.1–100 μg/ml), however, exhibited a more pronounced inhibitory effect on $^3$H-thymidine incorporation stimulated with bFGF (5 ng/ml) in the smooth muscle cells (n = 5, 3 females and 2 males; P < 0.05, Fig. 4 left).

3.2. Effects of estrogen on cell migration

PDGF-BB (0.01–10 ng/filter) induced a dose-dependent increase in the migration of human saphenous vein....
smooth muscle cells (Fig. 5A). The maximal effect occurred at 1 ng of PDGF-BB, where migration was stimulated more than 5-fold over control ($P < 0.05; n = 4$, 3 males and 1 female).

Prior incubation of smooth muscle cells with 17β-estradiol ($10^{-10} - 10^{-6}$ M) concentration-dependently inhibited PDGF-sinduced migration (Fig. 5B). The number of migrated smooth muscle cells was reduced at $10^{-9}$ M of 17β-estradiol ($P < 0.05$) and was maximal ($P < 0.005; n = 5$, 3 males and 2 females) at $10^{-6}$ M as compared with PDGF-BB alone.

4. Discussion

This study demonstrates that 17β-estradiol inhibits proliferation and migration of human vascular smooth muscle cells of saphenous veins stimulated by mitogens such as platelet-derived growth factor and basic fibroblast growth factor. Most interestingly, these antiproliferative and antimigratory effects of 17β-estradiol occurred in vascular smooth muscle cells obtained from postmenopausal women as well as from age-matched men with coronary artery disease.

Protective effects of estrogens against cardiovascular disease in postmenopausal women are well documented [5]. Putative mechanisms may involve endothelium-dependent and -independent vasodilation [10-14] and an improved lipid profile [5,15]. Furthermore, estrogen stimulates endothelial nitric oxide synthase activity in vivo [20], and may inhibit smooth muscle cell proliferation via endothelium-derived nitric oxide [21]. Proliferation and migration of vascular smooth muscle cells are believed to contribute significantly to intimal thickening in atherosclerosis, restenosis and venous bypass graft disease [2,3]. Experiments with cultured vascular smooth muscle cells obtained from rats and pigs, however, revealed inconsistent antiproliferative effects of 17β-estradiol [22,23], suggesting important species differences or vessel differences. This study provides the first evidence that 17β-estradiol inhibits smooth muscle cell proliferation in postmenopausal women and also in men with coronary artery
In unstimulated cultured human vascular smooth muscle cells, 17β-estradiol alone exerted no significant effects in line with the observation by Calcagno et al. who did not find antiproliferative effects of estrogen on 3H-thymidine uptake in human saphenous vein organ culture [24] when the vessels were not stimulated with growth factors. However, in cells stimulated with either platelet-derived growth factor or basic fibroblast growth factor, 17β-estradiol inhibited 3H-thymidine uptake of these cells, although the effect was much weaker than heparin. In contrast to 17β-estradiol, the steroid, dexamethasone, which has been shown to exert antiproliferative effects in diseased (atherosclerotic) smooth muscle cells [25] and inhibits intimal thickening in rat carotid artery after balloon injury [26], had no effects on DNA synthesis in these venous smooth muscle cells. The different observations between the present study and those previous studies may be due to the different cell types and species used. In addition, 17β-estradiol reduced the increase in cell numbers evoked by platelet-derived growth factor. These results, therefore, indicate that 17β-estradiol specifically interferes with the effects of growth factors in vascular smooth muscle cells. The fact that the antiproliferative effects of 17β-estradiol were comparable in cells obtained from postmenopausal women to those from age-matched men indicates that vascular smooth muscle can respond to 17β-estradiol regardless of gender, at least at this age stage. Whether smooth muscle cells from premenopausal women have similar behavior remains unclear. The concentrations used in the present study to inhibit cell proliferation are beyond the physiological range in vivo, but are the same as those used in other studies which demonstrated acute effects of the hormone on the blood vessel wall [17,27]. It is conceivable, however, that with prolonged exposure to estrogens similar effects on blood vessel wall may occur even at physiological concentrations.

In addition to proliferation, migration of vascular smooth muscle cells contributes significantly to vascular structural changes occurring in atherosclerosis, restenosis and venous graft disease [3,4,28–30]. In this study, 17β-estradiol was most effective in inhibiting migration of human vascular smooth muscle cells induced by platelet-derived growth factor. It has been discussed that migration of smooth muscle cells from the media into the intima accounts in large part for the accumulation of this cell type in atherosclerotic as well as intimal hyperplasia occurring after balloon injury [4,28–30]. The evolving concept of vascular remodeling [4] may also involve considerably the migratory responses of smooth muscle cells of the media.

The cellular mechanisms of the antiproliferative and antimigratory effects of 17β-estradiol may involve several pathways. The classical pathway utilized by 17β-estradiol and related steroids involves activation of the estrogen receptor [31]. This receptor is located intracellularly and is translocated into the nucleus after binding of its specific ligand [31]. RT-PCR demonstrated mRNA expression of estrogen receptors in vascular smooth muscle cells of both female and male patients (data not shown). This is in agreement with previous studies and further for the first time demonstrates that the receptor is expressed regardless of the gender of cells [32]. Compared to MCF-7 cells, a mammary carcinoma cell line [32], and human umbilical vein endothelial cells, the expression levels were lower. Also, Northern blot analysis did not reveal a reliable signal in vascular smooth muscle cells (unpublished observation) as observed by others as well [32], suggesting that the degree of receptor expression is lower than in tissue obtained from the mammary gland or sexual organs or endothelial cells. Phenol red interferes with estrogen receptors [33] and in this study prevented the inhibitory effects of 17β-estradiol on proliferation induced by platelet-derived growth factor. However, it is still unclear whether the estrogen receptor mediates these effects of the hormone in these particular cells, since estrogens also bind to membrane associated binding sites [34] and three splicing variants of estrogen receptors in addition to the wild type of the receptor have been identified in rat vascular smooth muscle cells by a recent study [35].

**Acknowledgements**

This study was supported by the Swiss National Research Foundation (No. 32-32541.91), the Swiss Cardiology Foundation, the Schweizerische Mobiliarversicherung, the Ciba-Foundation and Patria Insurance.
References


